Here, we comment on the potential of CFTR functional tests in patient-derived intestinal organoids (PDIOs) to enhance early risk stratification in CFSPID/CRMS cases. The gene discussed is CFTR; the disease is CFTR-related metabolic syndrome/CF screen positive, inconclusive diagnosis.